On June 26, the medical network, as the largest terminal of drug sales, guided the structure and direction of domestic drug use. Judging from the performance of the pharmaceutical market from 2005 to 2016, hospital terminal sales volume has been growing continuously. Drug sales have slowed to around 10% from around 20% a few years ago. In 2016, sample hospital sales grew by 9.1%, a slight increase from 2015.
The market increased five times in ten years
According to the domestic sample hospital data, in 2016, the PDB sample hospital covered 20 categories, with more than 2,200 varieties and more than 2,500 enterprises. The overall market increased from 32.69 billion yuan in 2005 to 166.15 billion yuan in 2016. The overall market grew 5.1 times, and the compound growth rate was 16.9 percent from 2005 to 2016.
The field of drug use accounted for 87.2%
In 2016, the top 10 areas for drug use in domestic sample hospitals were: 25.1 billion yuan in anti-infective drug sales, a 7.9% increase over the same period. The sales volume of cardiovascular system was 199.7 billion yuan, which was up 4.7 percent over the same period. Sales of blood and hematopoietic system were 18.51 billion yuan, a 9.5 percent increase over the same period. Anti-tumor drug sales volume was 16.98 billion yuan, an increase of 11.2% over the same period. The sales of the nerve system were 15.17 billion yuan, up 9.7% over the same period. Sales of the drug used in the digestive system were 14.14 billion yuan, an increase of 8.2% over the same period. Sales of immuno-adjusted agents were 12.65 billion yuan, up 7.5% over the same period. Sales of endocrine and metabolic regulation were 9.86 billion yuan, up 9.1% over the same period. Miscellaneous sales totaled 7.56 billion yuan, up 12.6% over the same period. Sales of respiratory drugs were 50.0 billion yuan, up 12.5 percent over the same period. The top 10 areas accounted for 87.2 percent of the overall market, and the areas with rapid growth were both anti-tumor and respiratory drugs, with a growth rate of more than 10.0%.
The number of drug use in the sample hospital in 2016 was in the 11th ~ 20 major areas: sales of biotech drugs were 4.58 billion yuan, up 9.2% from the same period. Sales of bone and muscle drugs were 4.22 billion yuan, up 9.1% from the same period. The sales of mental disorders were 3.00 billion yuan, up 13.1% over the same period. Sales of narcotic drugs and auxiliary drugs were 2.48 billion yuan, up 12.2% over the same period. The sales of drug and sex hormones in the reproductive system were 2.33 billion yuan, up by 21.1% over the same period. The sales volume of sensory organs was 1.52 billion yuan, an increase of 12.8% over the same period. The sales of dermatological drugs were 1.16 billion yuan, up 10.1 percent from the same period. The sales volume of drug administration in the urinary system was 810 million yuan, an increase of 12.2% over the same period. Sales of anti-allergic drugs were 780 million yuan, up 15.3% over the same period. Pharmaceutical sales of raw materials and non-direct effects were 0.4 billion yuan, up 41.2 percent over the same period. In the areas of rapid growth, there were three major areas: mental disorders, drugs, drugs, drugs and sex hormones, and the growth rate exceeded 10.0%.
In the top 20 fields, there are seven areas of the overall market has more than 10 billion yuan, among them, two areas has exceeded 20 billion yuan, or nearly 20 billion yuan, respectively is: anti-infective medicine sales of 25.1 billion yuan. The sales volume of cardiovascular system was 199.7 billion yuan.
TOP 100 medicines account for 50%
According to statistics, the total drug purchase amount of the first 100 drugs in the sample hospital in 2016 was 83.09 billion yuan, accounting for 50.0% of the overall market. The top 50 drug purchases were 55.26 billion yuan, 33.3% of the total market. The top 10 drug purchases were 17.51 billion yuan, or 10.5% of the total market. Among the TOP 10 products, the sales of human blood albumin were 23.1 billion yuan, up 14.6% from the same period. The sales of entecavir were 1.71 billion yuan, up 16.2% from the same period. Atorvastatin sales were 1.58 billion yuan, up 10.1 percent from the same period. The above three product growth rate exceeded 10.0%, showing good growth. |
